Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

ABSTRACT: Breast cancer characterized by overexpression of human epidermal growth factor receptor 2 (HER2) has been associated with more aggressive disease progression and a poorer prognosis. Although an improved understanding of breast cancer pathogenesis and the role of HER2 signaling has resulted in significant survival improvements in the past 20 years, resistance to HER2-targeted therapy remains a concern. A number of strategies to prevent or overcome resistance to HER2-targeted therapy in breast cancer are being evaluated. This article provides a comprehensive review of (a) the role of HER2 signaling in breast cancer pathogenesis, (b) potential receptor and downstream therapeutic targets in breast cancer to overcome resistance to HER2-targeted therapy, and (c) clinical trials evaluating agents

SUBMITTER: Eroglu Z 

PROVIDER: S-EPMC3926785 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature